Tuomo Alanko

5.3k total citations
32 papers, 947 citations indexed

About

Tuomo Alanko is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Tuomo Alanko has authored 32 papers receiving a total of 947 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 7 papers in Genetics. Recurrent topics in Tuomo Alanko's work include Cancer Immunotherapy and Biomarkers (9 papers), CAR-T cell therapy research (8 papers) and Prostate Cancer Treatment and Research (8 papers). Tuomo Alanko is often cited by papers focused on Cancer Immunotherapy and Biomarkers (9 papers), CAR-T cell therapy research (8 papers) and Prostate Cancer Treatment and Research (8 papers). Tuomo Alanko collaborates with scholars based in Finland, United States and France. Tuomo Alanko's co-authors include Petri Bono, Olli Saksela, Tuija Poussa, Leena‐Maija Soveri, Pia Österlund, Helena Isoniemi, Heikki Joensuu, R. Kokko, Taina Turpeenniemi‐Hujanen and R. Asola and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Tuomo Alanko

29 papers receiving 924 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tuomo Alanko Finland 12 717 252 251 190 165 32 947
Delicia Carey United States 15 596 0.8× 491 1.9× 357 1.4× 84 0.4× 221 1.3× 21 1.2k
Tamar Hamburger Israel 19 444 0.6× 397 1.6× 246 1.0× 214 1.1× 33 0.2× 55 911
Ashok K. Vaid India 15 781 1.1× 188 0.7× 116 0.5× 259 1.4× 193 1.2× 54 1.1k
RS Camplejohn United Kingdom 18 716 1.0× 425 1.7× 88 0.4× 417 2.2× 202 1.2× 27 1.2k
Burke J. Brooks United States 15 889 1.2× 665 2.6× 172 0.7× 191 1.0× 115 0.7× 24 1.7k
Hiroshi Nakagomi Japan 16 558 0.8× 272 1.1× 158 0.6× 242 1.3× 60 0.4× 58 1.2k
Matthew D. Callister United States 10 785 1.1× 301 1.2× 55 0.2× 225 1.2× 55 0.3× 20 1.0k
Joseph J. Stephenson United States 8 426 0.6× 275 1.1× 162 0.6× 326 1.7× 56 0.3× 13 888
Conway Gee United States 11 470 0.7× 334 1.3× 47 0.2× 204 1.1× 28 0.2× 14 926

Countries citing papers authored by Tuomo Alanko

Since Specialization
Citations

This map shows the geographic impact of Tuomo Alanko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tuomo Alanko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tuomo Alanko more than expected).

Fields of papers citing papers by Tuomo Alanko

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tuomo Alanko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tuomo Alanko. The network helps show where Tuomo Alanko may publish in the future.

Co-authorship network of co-authors of Tuomo Alanko

This figure shows the co-authorship network connecting the top 25 collaborators of Tuomo Alanko. A scholar is included among the top collaborators of Tuomo Alanko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tuomo Alanko. Tuomo Alanko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Peltola, Katriina, Tuomo Alanko, Teijo Pellinen, et al.. (2025). Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial. Journal for ImmunoTherapy of Cancer. 13(1). e010493–e010493. 2 indexed citations
2.
Santos, João M., Matthew S. Block, Johanna Mäenpää, et al.. (2024). PROTA: A phase I clinical trial combining an oncolytic adenovirus encoding for TNFa and IL-2 with pembrolizumab for the treatment of platinum-resistant or -refractory ovarian cancer.. Journal of Clinical Oncology. 42(16_suppl). 5562–5562.
3.
Antonarakis, Emmanuel S., Josep M. Piulats, Marine Gross‐Goupil, et al.. (2021). 611P Pembrolizumab (pembro) monotherapy for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Updated analyses with 4 years of follow-up from cohorts 1-3 of the KEYNOTE-199 study. Annals of Oncology. 32. S651–S652. 7 indexed citations
4.
Iivanainen, Sanna, et al.. (2020). Follow-Up of Cancer Patients Receiving Anti-PD-(L)1 Therapy Using an Electronic Patient-Reported Outcomes Tool (KISS): Prospective Feasibility Cohort Study. JMIR Formative Research. 4(10). e17898–e17898. 21 indexed citations
5.
Goh, Jeffrey C., Josep M. Piulats, Marine Gross‐Goupil, et al.. (2020). 231P Phase II study of pembrolizumab in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC): Updated follow-up of cohorts (C) 1-3 from KEYNOTE-199. Annals of Oncology. 31. S1331–S1332. 2 indexed citations
6.
Antonarakis, Emmanuel S., Josep M. Piulats, Marine Gross‐Goupil, et al.. (2020). Update on KEYNOTE-199, cohorts 1-3: Pembrolizumab (pembro) for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 38(6_suppl). 104–104. 4 indexed citations
7.
Antonarakis, Emmanuel S., Marine Gross‐Goupil, Jeffrey C. Goh, et al.. (2020). Biomarker analysis from the KEYNOTE-199 trial of pembrolizumab in patients (pts) with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 38(15_suppl). 5526–5526. 11 indexed citations
8.
Joensuu, Timo, Kalevi Kairemo, Timo Kiljunen, et al.. (2016). Multimodal Primary Treatment of Metastatic Prostate Cancer with Androgen Deprivation and Radiation. Anticancer Research. 36(12). 6439–6448. 11 indexed citations
9.
Kiljunen, Timo, Aki Kangasmäki, Kalevi Kairemo, et al.. (2014). VMAT technique enables concomitant radiotherapy of prostate cancer and pelvic bone metastases. Acta Oncologica. 54(6). 847–853. 11 indexed citations
10.
Österlund, Pia, Reetta Peltonen, Tuomo Alanko, Petri Bono, & Helena Isoniemi. (2014). A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection. OncoTargets and Therapy. 7. 1177–1177. 2 indexed citations
11.
Kanerva, Anna, Petri Nokisalmi, Iulia Diaconu, et al.. (2013). Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus. Clinical Cancer Research. 19(10). 2734–2744. 144 indexed citations
12.
Pesonen, Sari, Iulia Diaconu, Lotta Kangasniemi, et al.. (2012). Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients. Cancer Research. 72(7). 1621–1631. 107 indexed citations
13.
Joensuu, Heikki, Peter Bono, Vesa Kataja, et al.. (2009). S24 Update of the FINHER trial based on 5 years of follow-up. The Breast. 18. S10–S10. 5 indexed citations
14.
Joensuu, Heikki, Liisa Sailas, Tuomo Alanko, et al.. (2009). Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial. Annals of Oncology. 21(5). 968–973. 19 indexed citations
15.
Willebrand, Maria von, et al.. (2005). FGF‐2 blocks TGF‐β1‐mediated suppression of Bcl‐2 in normal melanocytes. Experimental Dermatology. 14(3). 202–208. 9 indexed citations
16.
Alanko, Tuomo & Olli Saksela. (2000). Transforming Growth Factor β1 Induces Apoptosis in Normal Melanocytes but not in Nevus Cells Grown in Type I Collagen Gel. Journal of Investigative Dermatology. 115(2). 286–291. 15 indexed citations
17.
Alanko, Tuomo, et al.. (1999). FGF Expression Allows Nevus Cells to Survive in Three-Dimensional Collagen Gel Under Conditions that Induce Apoptosis in Normal Human Melanocytes. Journal of Investigative Dermatology. 113(1). 111–116. 45 indexed citations
18.
Alanko, Tuomo, Jukka Tienari, Eero Lehtonen, & Olli Saksela. (1996). FGF-2 Inhibits Apoptosis in Human Teratocarcinoma Cells during Differentiation on Collagen Substratum. Experimental Cell Research. 228(2). 306–312. 6 indexed citations
19.
Alanko, Tuomo, Jukka Tienari, Eero Lehtonen, & Olli Saksela. (1994). Development of FGF-Dependency in Human Embryonic Carcinoma Cells after Retinoic Acid-Induced Differentiation. Developmental Biology. 161(1). 141–153. 8 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Delicia Carey Breakdown of academic impact, for papers by Tamar Hamburger Breakdown of academic impact, for papers by Ashok K. Vaid Breakdown of academic impact, for papers by RS Camplejohn Breakdown of academic impact, for papers by Burke J. Brooks Breakdown of academic impact, for papers by Hiroshi Nakagomi Breakdown of academic impact, for papers by Matthew D. Callister Breakdown of academic impact, for papers by Joseph J. Stephenson Breakdown of academic impact, for papers by Conway Gee
Rankless by CCL
2026